Wefight
Montpellier, 34000, France
NCT Number: NCT04337047
There are many scales for screening or assessing the impact of a disease. These scales are generally used to diagnose or assess the severity of a disease and are carried out at the request of a physician by the patient. Conversational agents could make it possible to administer these questionnaires remotely, analyse them and use the results on a large scale, without prior medical intervention.
The main objective of this study is to quantify and qualify the distress of a large population in times of pandemic crisis.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Montpellier, 34000, France
The Peritraumatic Distress Inventory is the standard tool designed to assess distress in times of crisis. It consists of 13 questions.
Questions will be submitted to the participants from the Vik chatbot. Responses will be analysed and compared according to the demographics and pathologies encountered.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
questionnaire assesment
Time frame: 1 month
Time frame: 1 month
Wefight
Industry
Distress During the COVID-19 Pandemic in France: a National Assessment of At-risk Populations
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07731464
Anxiety, Anxiety Disorders
Islamabad, Federal, Pakistan
View Trial DetailsNCT07255365
Anxiety, Anxiety Disorders
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT02257853
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT06085105
Adverse Outcomes, Behavior
Navrongo, Ghana
View Trial Details